{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:06:05Z","timestamp":1781100365347,"version":"3.54.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC"},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We present a post hoc analysis of viral blips (HIV-1 RNA \u226550\u2005copies\/mL between 2 values of &amp;lt;50\u2005copies\/mL) in the DRIVE-FORWARD and DRIVE-AHEAD doravirine (DOR) Phase 3 studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults living with untreated HIV-1 were randomized (1:1) to a DOR-containing regimen or comparator (darunavir\/ritonavir- or efavirenz-containing), each with 2 nucleos(t)ide reverse transcriptase inhibitors, for 96 weeks (double-blind base), followed by 96 weeks of a DOR-containing regimen (open-label extension). Cox proportional hazards models were used to analyze relationships between frequency of blips, baseline characteristics, and virologic rebound (2 consecutive HIV-1 RNA \u226550\u2005copies\/mL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the base studies, blips occurred in 11.1%\u201311.9% of participants who received DOR and 12.1%\u201315.4% who received comparator. In the extensions, blips occurred in 5.5%\u20137.9% of participants. Baseline HIV-1 RNA \u2264100 000\u2005copies\/mL was associated with lower likelihood of blips in the base studies (hazard ratio [HR], 0.41; [95% CI, 0.29\u20130.58]) and in participants who continued DOR in the extensions (0.41 [0.19\u20130.87]). Baseline CD4+ T-cell count \u2264200\u2005cells\/mm3 was associated with increased likelihood of blips in participants who switched to DOR (3.47 [1.43\u20138.43]). Virologic rebound occurred in 7.0% of participants in the base studies and 3.8% in the extensions. Virologic rebound was more common in participants with blips versus no blips in the base studies (13.6% vs 6.1%; 3.79 [2.32\u20136.18]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Blips were associated with increased risk of virologic rebound during the base study, and blips were less likely in participants with lower baseline HIV-1 RNA. Doravirine and comparator groups had similar rates of viral blips.<\/jats:p>\n                    <jats:p>Clinical Trials Registration. \u00a0ClinicalTrials.gov NCT02275780, NCT02403674<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag258","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:31:41Z","timestamp":1781004701000},"source":"Crossref","is-referenced-by-count":0,"title":["Analysis of Viral Blips Through Week 192 of the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Studies of Doravirine-Based Regimens in Adults Living With Previously Untreated HIV-1"],"prefix":"10.1093","volume":"13","author":[{"given":"Jean-Michel","family":"Molina","sequence":"first","affiliation":[{"name":"St-Louis and Lariboisi\u00e8re Hospitals, APHP, University of Paris Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6168-6745","authenticated-orcid":false,"given":"Chloe","family":"Orkin","sequence":"additional","affiliation":[{"name":"SHARE Collaborative, Blizard Institute, Queen Mary University of London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6553-691X","authenticated-orcid":false,"given":"Roger","family":"Paredes","sequence":"additional","affiliation":[{"name":"Hospital Germans Trias i Pujol, Badalona and Universitat Polit\u00e8cnica de Catalunya\u2013Barcelona HealthTech , Terrassa ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Jin","family":"Xu","sequence":"additional","affiliation":[{"name":"MRL, Merck & Co., Inc. , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Hsiu","family":"Su","sequence":"additional","affiliation":[{"name":"MRL, Merck & Co., Inc. , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Asante-Appiah","sequence":"additional","affiliation":[{"name":"MRL, Merck & Co., Inc. , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4976-0792","authenticated-orcid":false,"given":"Rebeca M","family":"Plank","sequence":"additional","affiliation":[{"name":"MRL, Merck & Co., Inc. , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Lahoulou","sequence":"additional","affiliation":[{"name":"MRL, Merck & Co., Inc. , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2026061009402804700_ofag258-B1","author":"UNAIDS"},{"key":"2026061009402804700_ofag258-B2","author":"World Health Organization","year":"2016"},{"key":"2026061009402804700_ofag258-B3"},{"key":"2026061009402804700_ofag258-B4","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/00002030-200210180-00008","article-title":"Prevalence and clinical correlates of HIV viremia (\u2018blips\u2019) in patients with previous suppression below the limits of quantification","volume":"16","author":"Sklar","year":"2002","journal-title":"AIDS"},{"key":"2026061009402804700_ofag258-B5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/135965350200700404","article-title":"Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure","volume":"7","author":"Mira","year":"2002","journal-title":"Antivir Ther"},{"key":"2026061009402804700_ofag258-B6","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1097\/00002030-200209270-00017","article-title":"Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy","volume":"16","author":"Greub","year":"2002","journal-title":"AIDS"},{"key":"2026061009402804700_ofag258-B7","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1097\/QAD.0000000000002306","article-title":"Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy","volume":"33","author":"Fleming","year":"2019","journal-title":"AIDS"},{"key":"2026061009402804700_ofag258-B8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/QAI.0000000000002898","article-title":"Lower incidence of HIV-1 blips observed during integrase inhibitor-based combination antiretroviral therapy","volume":"89","author":"Dijkstra","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026061009402804700_ofag258-B9","author":"US Department of Health and Human Services","year":"2025"},{"key":"2026061009402804700_ofag258-B10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12879-016-1628-6","article-title":"Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels","volume":"16","author":"S\u00f6rstedt","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2026061009402804700_ofag258-B11","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/cid\/ciz129","article-title":"Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure","volume":"69","author":"Joya","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026061009402804700_ofag258-B12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/cid\/ciac762","article-title":"Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European multicenter cohort","volume":"76","author":"Elvstam","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026061009402804700_ofag258-B13","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/infdis\/jis104","article-title":"Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis","volume":"205","author":"Grennan","year":"2012","journal-title":"J Infect Dis"},{"key":"2026061009402804700_ofag258-B14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jama.286.2.171","article-title":"Prevalence and predictive value of intermittent viremia with combination HIV therapy","volume":"286","author":"Havlir","year":"2001","journal-title":"JAMA"},{"key":"2026061009402804700_ofag258-B15","author":"US Department of Health and Human Services","year":"2024"},{"key":"2026061009402804700_ofag258-B16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/QAI.0b013e3181d01d1d","article-title":"Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep\/COBAS TaqMan HIV-1 version 1.0 viral load test","volume":"54","author":"Willig","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026061009402804700_ofag258-B17","volume-title":"PIFELTRO [prescribing information]","year":"2024"},{"key":"2026061009402804700_ofag258-B18","volume-title":"DELSTRIGO\u2122 [prescribing information]","year":"2025"},{"key":"2026061009402804700_ofag258-B19","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2026061009402804700_ofag258-B20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus\u20131 infection: week 48 results of the DRIVE-AHEAD trial","volume":"68","author":"Orkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026061009402804700_ofag258-B21","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/S2352-3018(19)30336-4","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial","volume":"7","author":"Molina","year":"2020","journal-title":"Lancet HIV"},{"key":"2026061009402804700_ofag258-B22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/cid\/ciaa822","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate (TDF) versus efavirenz\/emtricitabine\/TDF in treatment-naive adults with human immunodeficiency virus type 1 infection: week 96 results of the randomized, double-blind, phase 3 DRIVE-AHEAD noninferiority trial","volume":"73","author":"Orkin","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026061009402804700_ofag258-B23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1021\/acsinfecdis.9b00178","article-title":"Rational design of doravirine: from bench to patients","volume":"6","author":"Hwang","year":"2020","journal-title":"ACS Infect Dis"},{"key":"2026061009402804700_ofag258-B24","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3018(23)00258-8","article-title":"Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials","volume":"11","author":"Orkin","year":"2024","journal-title":"Lancet HIV"},{"key":"2026061009402804700_ofag258-B25","volume-title":"Abbott Realtime HIV-1 [product insert]","year":"2011"},{"key":"2026061009402804700_ofag258-B26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/tmi.13951","article-title":"Investigating rates and predictors of viral blips, low-level viraemia and virological failure in the Australian HIV observational database","volume":"29","author":"Han","year":"2024","journal-title":"Trop Med Int Health"},{"key":"2026061009402804700_ofag258-B27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3851\/IMP2949","article-title":"Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study)","volume":"20","author":"Vandenhende","year":"2015","journal-title":"Antivir Ther"},{"key":"2026061009402804700_ofag258-B28","author":"US Department of Health and Human Services","year":"2024"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag258\/68504446\/ofag258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag258\/68504446\/ofag258.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T13:40:36Z","timestamp":1781098836000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag258\/8705114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag258","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"ofag258"}}